ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

In Brief: “…In Case Mrs. Lasker Happens To See A Senator”; White Potter Defend Center Progress

June 16, 1978

Obit: Same Shapiro, Proponent of Mammographic Screening.

January 7, 2000

CREG Announced for Premorbid Psychological Factors Study

August 27, 1976

Fred Conrad, MDA VP, Shot To Death In Hospital Office

January 7, 1983

NCAB Subcommittee Calls For Review Of Organ Site Program, Consideration Of One For Lung Cancer

May 1, 1981

ASCO Letter To NCI Urges Increased Support for Clinical Trials, Training, Translational Research

March 6, 2009